



Journal of Hospital Pharmacy

An Official Publication of Bureau for Health & Education Status Upliftment
(Constitutionally Entitled as Health-Education, Bureau)

A REVIEW ON ONSET OF SYSTEMIC LUPUS ERYTHEMATOUS FOLLOWED BY COVID-19

*Nithya.R^{*1}, Gayathri.M², Merlin Jose³, Monica.B⁴, Muthu selvi.R⁵*

^{*1}Assistant professor, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode- 637205, Namakkal Dist, Tamil Nadu, India.

(Affiliated to The Tamil Nadu Dr.M.G.R. Medical University, Chennai)

^{2,3,4,5} Doctor of Pharmacy- Intern Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode- 637205, Namakkal Dist, Tamil Nadu, India.

Affiliated to (The Tamil Nadu Dr.M.G.R. Medical University, Chennai)

* Corresponding author

Nithya R, Assistant Professor, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode-635207, Namakkal District, Tamil Nadu, India

Email Id: serviceheb@gmail.com

ABSTRACT: Covid-19 is an infectious disease caused by SARS-CoV-2 which has spread worldwide and lead to millions of deaths. Generally, patients who were infected with Covid-19 were left with weakened immune system and also with an increased risk for autoimmune disease. This eventually may result in lupus disease. Systemic Lupus Erythematosus is an one such autoimmune condition that causes inflammation throughout the body. Hence it is important to be conscious about the occurrence of SLE in Covid-19 patients to develop management techniques and to improve the outcome of these patients. In this review we tried to focus on the possibilities of SLE followed by COVID 19 infection, its pathophysiology and drug treatment based on various case studies reported worldwide.

Access this Article Online

Website: <http://www.journalofhospitalpharmacy.in>

Received on 04/03/2022

Accepted on 18/03/2022 © HEB All rights reserved

Quick Response Code:

